Full TitleDS3201-A-U102: A Phase I Study of DS-3201B In Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) that have come back despite prior therapy can be challenging to treat successfully. In this study, researchers are finding the highest dose of the investigational drug DS-3201b that can be given safely in patients with relapsed AML or ALL.
DS-3201b may work by blocking the activity of two proteins called EZH1 and EZH2, which are involved in cancer growth. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have AML or ALL that came back after prior therapy.
- At least 2 weeks must pass between the completion of previous treatment and entry into the study, and patients should recover from any serious side effects.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Raajit Rampal at 212-639-2194.